0.38
+0.0143(+3.91%)
Currency In USD
| Previous Close | 0.37 |
| Open | 0.38 |
| Day High | 0.4 |
| Day Low | 0.37 |
| 52-Week High | 1.4 |
| 52-Week Low | 0.37 |
| Volume | 4.14M |
| Average Volume | 6.06M |
| Market Cap | 127.97M |
| PE | -0.85 |
| EPS | -0.45 |
| Moving Average 50 Days | 0.45 |
| Moving Average 200 Days | 0.55 |
| Change | 0.01 |
If you invested $1000 in Sangamo Therapeutics, Inc. (SGMO) 10 years ago, it would be worth $56.34 as of January 22, 2026 at a share price of $0.38. Whereas If you bought $1000 worth of Sangamo Therapeutics, Inc. (SGMO) shares 5 years ago, it would be worth $25.44 as of January 22, 2026 at a share price of $0.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
GlobeNewswire Inc.
Dec 18, 2025 1:05 PM GMT
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support acce
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
GlobeNewswire Inc.
Dec 02, 2025 1:05 PM GMT
RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigati
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
GlobeNewswire Inc.
Nov 21, 2025 1:05 PM GMT
RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo’s request for a rolling submission and